Remaining Unmet Needs in the Third-Line and Lessons from HER2CLIMB
Drs Tripathy and Kaklamani emphasize the most critical unmet needs for patients with HER2+ metastatic breast cancer in the third-line or higher settings and recap what the field previously learned from the HER2CLIMB trial of tucatinib/trastuzumab/capecitabine.
Sara Hurvitz Breast Cancer Her2 Breast Cancer Her2 Positive Breast Cancer Metastatic Breast Cancer Third Line Therapy
Source: onclive.com